Ask AI
ProCE Banner Activity

Highlights from the RSV “Podcast Corner” Question and Answer Session

Clinical Thought

The respiratory syncytial virus (RSV) vaccine reduces the risks for severe disease and death in older adults and those with comorbidities, but it is up to us as healthcare professionals to get the word out and educate our patients about it. To understand more about the current RSV vaccine landscape, here are our answers to learner questions from our recent “Podcast Corner” question and answer session.

Released: July 23, 2025

Expiration: July 22, 2026

Share

Provided by

Provided by the American Association of Nurse Practitioners (AANP) in partnership with Practicing Clinicians Exchange (PCE)

ProCE Banner

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline

Partners

Practicing Clinicians Exchange, LLC

ProCE Banner

Disclosure

Primary Author

Ruth Carrico, PhD, DNP, APRN, FAAN: consultant/advisor/speaker: Moderna, Novavax, Pfizer, Sanofi, Seqirus, Valneva, VaxCare.

Audrey Stevenson, PhD, MPH, MSN, FNP-BC: speaker: GlaxoSmithKline, Sanofi, Seqirus; advisor: Sanofi.